- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
ANDA Litigation Settlements
2011/2012
Case Name | Drug | Patent No(s). | Publicly Available Terms |
---|---|---|---|
AstraZeneca Pharma. LP v. Accord Healthcare, 08-4804, 09-619 (D.N.J.) |
Seroquel XR®(quetiapine fumarate) |
5,948,437 |
Accord agreed not to sell generic Seroquel XR®until November 2016 ‘437 patent does not expire until 2017 |
Pfizer Inc. v. Actavis Group HF, 10-675 (D. Del.) |
Lipitor®(atorvastatin calcium) |
5,969,156 5,686,104 6,126,971 |
N/A |
AstraZeneca AB v. SunPharmaGlobalFZE, 10-1017 (D.N.J.) |
Nexium®I.V. (esomeprazole sodium) |
5,877,192 6,143,771 |
Sun Pharma agreed not to sell its generic drug until Jan. 2, 2014, without authorization |
Abbott Labs. v. Impax Labs. Inc., 10-1322 (D.N.J.) |
Trilipix®(fenofibric acid) |
7,259,186 |
Impax may launch generic product on Jan. 1, 2014, or as early as July 15, 2013, under certain undisclosed conditions ‘186 patent does not expire until 2025 |
Bristol-Myers Squibb Co. v. TevaPharma.USAInc., 09-919 (D. Del.) |
Reyatax®(atazanavir sulfate) |
5,849,911 6,087,383 |
Teva may launch generic product in July 2017, or earlier, under certain undisclosed conditions The ‘911 patent expires in June 2017 and the ‘383 patent expires in Dec. 2018 |
Pfizer Inc. v. AurobindoPharma. Ltd., 11-569 (D. Del.) |
Lipitor®(atorvastatin calcium) |
5,969,156 |
N/A |
Bayer Schering Pharma AG v. TevaPharma.USAInc., 09-480 (D. Del.) |
Levitra®(vardenafil HCl) |
6,362,178 7,696,206 |
N/A |
Vivelle Ventures LLC (Novartis) v. Mylan Tech. Inc., 11-1187 (S.D.N.Y.) Vivelle Ventures LLC (Novartis) v. Mylan Tech. Inc., 11-50 (D. Vt.) |
Vivelle Dot®(estradiol transdermal system) |
5,656,286 6,024,976 |
Mylan to receive a patent license to begin selling its generic product in Dec. 2013, subject to approval by USDOJ and FTC |
Valeant International (Barbados) SRL v. Par Pharma.Cos.Inc., 10-7310 (S.D.N.Y.) |
Aplenzin®(buproprion HBr extended release tablets) |
7,569,610 7,572,935 7,649,019 7,553,992 7,671,094 7,241,805 7,645,802 7,622,407 7,645,901 |
N/A |
Teva Women’s Health Inc. V. Lupin Ltd., 10-0080 (D.N.J.) |
LoSeasonique™ (ethinyl estradiol/levonorgestrel) |
7,615,545 |
Watson may launch generic product on 12/14/2011 |
Pfizer Inc. v. SandozInc., 09-0742 (D. Del.) |
Caduet®(amlodipine besylate/atorvastatin calcium) |
6,455,574 5,969,156 6,126,971 5,686,104 |
N/A |
Sanofi-Aventis v. SunPharma.Indus.Ltd., 08-6286 (S.D.N.Y.) |
Plavix®(clopidogrel bisulfate) |
6,429,210 |
N/A |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.